Rationale for antithrombotic therapy after aortic valve implantation
Calcific aortic stenosis (AS) is the most common type of valvular heart disease leading to intervention and represents a major healthcare burden. 1 Symptomatic severe AS has a poor prognosis when treated medically and inevitably leads to functional deterioration, heart failure, and death. 2 In recent years, transcatheter aortic valve implantation (TAVI) has been introduced as a less invasive treatment to prosthetic surgical replacement of the valve (SAVR) among high-risk and intermediaterisk patients particularly if transfemoral access is feasible. [3] [4] [5] [6] TAVI has been rapidly embraced, and it is estimated that >250 000 TAVI procedures have been performed in >65 countries worldwide (by the end of 2016). A wide spectrum of devices are currently in use ( Figure 1) . Despite improving experience and techniques, ischaemic and bleeding complications after TAVI remain prevalent and impair survival ( Table 1) . These complications are related to both the procedure itself but also over the long-term because of underlying risk factors ( Figure 2 
Mechanisms of thrombosis in patient undergoing transcatheter aortic valve implantation
The implanted bioprosthetic valve and the stent structure to which it is attached may add an additional prothrombotic environment contributing to cardioembolic risk in patients who are already at increased baseline risk of thrombo-embolic events. [10] [11] [12] Insertion of a prosthesis without removal of the calcified aortic valve creates an irregular zone around the valve frame with turbulent and often low shear flow patterns that may predispose to fibrin deposition, thrombus formation, and embolization beyond processes involved in normal healing. [10] [11] [12] Long-term data from bioprosthetic valve studies have indicated that neointimal tissue growth and endothelialization of the valve stent probably occur about 3 months after implantation, when the risk of stroke shows a corresponding decline thereafter.
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The elevated thrombo-embolic risk extends well beyond the procedure and persists during follow-up ( Figure 2 and Table 1) .
Cerebrovascular events
Ischaemic stroke may occur during or after TAVI, either in the first days or during long-term follow-up and are associated not only with considerable morbidity but also offset the prognostic gain of aortic valve intervention compared with patients without stroke. [3] [4] [5] [15] [16] [17] [18] Although the highest risk of clinically apparent stroke is 'front loaded' (within 48 h) after TAVI, the risk remains elevated for up to 3 months. 12, 19 Actually, one in four cerebrovascular events (CVEs) occur after 30 days and sometimes also after many months ( Table 1) . Early events are mainly procedural and related to device manipulation, post-valve deployment balloon dilation, and repeated prosthesis placement. 12, 20, 21 In fact, debris captured within embolic protection devices, during TAVI procedures, consist of thrombus, fibrin, calcified material, and tissue from the aortic wall or native leaflets.
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Subacute and late episodes are mainly of thrombo-embolic origin, which could arise from the stent of the implanted valves, but more frequently from atrial fibrillation (AF) occurrence. The prevalence of AF in elderly TAVI patients amounts to 30-50%. Moreover, 10-15% of patients develop new-onset AF (which is often clinically silent or unrecognized) after the procedure. 3, 25 Newonset AF has been identified as one of the strongest procedurerelated predictors for CVEs within 30 days after the procedure. 25, 26 The baseline cardioembolic risk of patients undergoing TAVI is high (mean CHADS 2 score 3). 25, 27 Acknowledging that clinical stroke after TAVI can be a devastating complication, it may be only the tip of the iceberg of cardioembolic sequelae. 28 Silent CVEs after TAVI are the hidden part of this iceberg, occurring in three-quarters of cases, irrespective of the device or vascular access used. The prognostic impact of clinical stroke is well established, but the potential long-term deleterious impact of silent CVEs remains largely unknown, and they may be associated with an increased risk of dementia and an early decline in cognitive function.
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Bioprosthetic valve thrombosis
Clinical transcatheter heart valve thrombosis is more common than previously considered. 18, [30] [31] [32] [33] [34] [35] [36] The risk of clinical thrombosis appears highest within the first 3 months after implantation (before endothelialization occurs), is likely to be sustained over a period of years (with an incidence of 0.03-0.07%/year). 18, 30, 33, 37 Jose et al. 34 reported an overall rate of 2.8% (4.8% in patients on antiplatelet drugs alone) median time to diagnosis of 181-days (interquartile range: 25-297days) in a large single centre cohort.
Although we currently lack a precise understanding of mechanisms leading to clinical thrombosis, the underlying principles invariably relate to perturbations in blood flow and activation of various haemostatic factors involving mechanisms common to medical deviceinduced thrombosis. 33 34 Transcatheter valve thrombosis may consist a spectrum, presenting as imaging abnormalities with normal gradients, increased gradients (and N-terminal pro-brain natriuretic peptide levels) without 
symptoms, and elevated gradients with clinical manifestations, including heart failure, thrombo-embolism, or valve failure ( Figure 3) . 34 Early reduced leaflet motion (RLM) and hypo-attenuated leaflet thickening (HALT) post-TAVI can be detected in up to 10% of patients by advanced CT image processing (three-and fourdimensional volume-rendered CT). 32, 35, 36, [38] [39] [40] The course of leaflet restriction appears fundamentally different depending on the presence or absence of anticoagulation, with consistent regression under vitamin-K antagonists [target international normalized ratio (INR) 2.0-3.0], but mostly progression under conventional dual antiplatelet therapy (DAPT) alone. 34, 41, 42 The observed regression under anticoagulation supports the concept that leaflet thrombosis is the underlying mechanism of early leaflet thickening. 34 Changes in leaflet thickening are associated with changes in transvalvular pressure gradients. Ultimately, this process can result in valve degeneration and failure and exposes patient to the risk of a re-intervention. 33, 34 In a recent report from the Mayo Clinic pathology department, bioprosthetic valve thrombosis contributed to 11.3% of cases of bioprosthetic valve dysfunction referred for re-intervention and occurred even several years after surgery. 18 The association between HALT, abnormal valve haemodynamics and stroke is debated. 41, 43 Notwithstanding this, it remains to be determined whether HALT and RLM are a clinically meaningful adverse events (i.e. an early marker of thrombosis, CVEs, and valve degeneration) or represents a subclinical imaging phenomenon. 41 
Venous thrombo-embolism
Venous thrombo-embolism (VTE) is a major contributor to the overall disease burden in elderly patients in general involving interactions between acquired or inherited predispositions to thrombosis and various other risk factors. 44, 45 Venous thrombo-embolism is a fairly common event, the annual average incidence increases exponentially with age to up to 1% in patients >80 years old. 44 ,46,47 Strong risk factors for VTE beyond older age include surgery, vascular manipulation, and immobilization. Thrombosis can affect any venous circulation, which includes deep vein thrombosis (DVT) of the leg or pelvis, and its complication, pulmonary embolism. The lack of published data on VTE incidence following TAVI is notable.
Myocardial infarction
Transcatheter aortic valve implantation is systematically associated with some degree of serum creatine kinase-MB (CK-MB) or cardiac troponin release reflecting the occurrence of periprocedural myocardial injury. A higher degree of injury is an independent predictor of 30-day and 1 year all-cause and cardiac mortality. 48, 49 The identification of obstructive coronary stenoses resulting in myocardial ischaemia is not trivial in patients with severe AS. 50 Concurrent coronary artery disease (CAD) is present in 34-75% of patients with severe AS undergoing TAVI and is associated with impaired outcomes. 51, 52 Both diseases share a number of risk factors, including male gender, diabetes mellitus, arterial hypertension, chronic kidney disease, and age. 53 The prognostic impact of CAD after TAVI (and revascularization) appears to vary based on the anatomic extent and complexity of the disease as quantified by the (residual) SYNTAX score.
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Bleeding
Early and late bleeding events after TAVI are observed frequently and have an adverse effect on long-term prognosis. 16, 55, 56 They may be categorized by severity as minor, major, or in life-threatening according to the Valve Academic Research Consortium (VARC) consensus definitions. 16, 24 In the Placement of Aortic Trancatheter Valve (PARTNER) I trial, 11.3% of patients developed a major bleeding complication (modified 
Valve Academic Research Consortium Definitions) within 30 days after the intervention. 55 In-hospital bleeding results in an increased risk of mortality [hazard ratio (HR) 6.1; 95% CI 2.9-12.9] within the first 30 days after the intervention, with no additional hazard arising between 30 days and 12 months. 16 Early, in-hospital, major bleeding complications after TAVI are related to vascular complications or injury to cardiac structures (e.g. pericardial tamponade). 55 Twothirds of early bleeding events are attributed to the access site and are considered vascular-or access-related complications. Late bleeding events (> _30 days) after TAVI occurred in approximately 6% of patients in the PARTNER I trial at a median time of 132 days (interquartile range: 71-230 days) after the index procedure. Major bleeding events beyond the peri-procedural period were associated with a fourfold (adjusted HR 3.91; 95% CI 2.67-5.71; P < 0.001) increase in mortality after 12 months of follow up. 56 Late events may be attributed to patients' bleeding susceptibility, but postoperative antiplatelet and thrombotic management played a substantial role in this frail and vulnerable patient population. Neurological (15.5%) and gastrointestinal (40.8%) complications were among the most frequent late bleeding complications beyond 30 days of followup. 55 Angiodysplastic gastrointestinal bleeding is seen in association with an acquired von Willebrand factor deficiency, a condition known as Heyde's syndrome. 57, 58 This abnormal condition is corrected shortly after TAVI but not after balloon valvuloplasty.
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Antithrombotic therapeutic options
With insufficient evidence regarding appropriate adjunct antithrombic pharmacotherapy during and after TAVI procedures, clinicians have resorted to extrapolating from related surgical and percutaneous procedures and clinical consensus. However, the level of evidence of antithrombotic therapy is rather limited in relation to SAVR, and valve types and patients differ considerably. Due to changing aetiology of complications over time, antiplatelet and anticoagulant therapy after TAVI should be carefully balanced. Extrapolating what we know from coronary or peripheral vascular stenting procedures is equally fraught due to differences in valve prosthetic material, patient populations, and technical considerations.
Pretreatment
A strategy of routine dual antiplatelet pretreatment with clopidogrel in patients undergoing TAVI has been abandoned by most centres because of a perceived increase in bleeding risk without a demonstrated reduction in ischaemic risk. 61 Most patients have high residual platelet reactivity after pretreatment with 300 mg clopidogrel. 62 
Adjunct antithrombotic treatment during transcatheter aortic valve implantation
Unfractionated heparin (UFH) is the most common agent for anticoagulation during TAVI procedures ( Table 2 ). In the PARTNER randomized studies, UFH was administered as a parenteral bolus of 5000 IU followed by additional doses to achieve an activated clotting time > _250 s. 20 
Adjunct antithrombotic treatment after transcatheter aortic valve implantation
Two competing hypotheses surround recommendations regarding long-term antithrombotic therapy after TAVI, namely the antithrombin and antiplatelet hypotheses. Unfortunately, data to indicate whether presumed thrombo-embolic events after TAVI are primarily due to platelet-based or thrombin-based clot formation are lacking. There are no uniform recommendations regarding antithrombotic therapy after SAVR for patients in sinus rhythm amongst guidelines ( Table 2) Grade 2C) . 65 Therefore, some but not all guidelines recommend
VKAs within the first 3-6 months after SAVR, whereas aspirin may be preferred for long-term treatment. Of note, all guidelines call for lifelong anticoagulation in patients with other risk factors such as AF. The current recommendations pertaining to antithrombotic treatment after TAVI in patients in sinus rhythm are largely based on expert consensus (Table 2) ; namely, the use of DAPT with aspirin (indefinitely) and clopidogrel (3-6 months) to obviate the metallic stent-mediated risk of thrombosis/embolization followed by longterm single antiplatelet therapy with aspirin alone. 68, 69 Dual antiplatelet therapy is also indicated for those TAVI patients with concomitant obstructive CAD after stent placement. Nevertheless, the benefits of DAPT after TAVI in patients in sinus rhythm remain controversial. A pooled analysis of individual patient data from four small trials, including in total 672 participants, suggested that the addition of clopidogrel to aspirin did not improve efficacy and safety. 70 However, this study remains inconclusive in view of several limitations, including the relatively low statistical power, inclusion of randomized and nonrandomized studies, and short duration of follow-up. The benefits and risks of long-term oral anticoagulation compared with an antiplatelet-based strategy involving DAPT or single antiplatelet therapy with aspirin, prasugrel, or ticagrelor needs to be addressed carefully. These issues are being investigated in the Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation (POPular-TAVI) trial. 69 POPular-TAVI is a multicentre open-label RCT with an all-comers design to test the safety, net-clinical benefit, and efficacy of omission of clopidogrel compared with a strategy using aspirin (< _100 mg o.d. for at least 1 year, recommended life-long) plus clopidogrel (75 mg o.d. for 3 months) or an oral anticoagulant (OAC, a VKA) in combination with clopidogrel in 1000 patients during 1 year of follow-up. Patients are randomized before the TAVI. In patients receiving a VKA, the procedure will be performed during uninterrupted therapy. The hypothesis is that the omission of clopidogrel in the first 3 months after TAVI may be safer and similarly effective than the addition of clopidogrel to aspirin or an OAC. For patients with an indication for an OAC undergoing TAVI (e.g. AF, DVT, or mechanical mitral valve prosthesis), the best treatment regimen after TAVI is unknown, but a combination of an OAC and aspirin or P2Y 12 inhibitor is frequently used. 65, 71 However, prescribing antiplatelet therapy for patients with AF after TAVI who are already on long-term anticoagulation may not confer additional benefits and can expose patients to added bleeding risk. In a recent study by Abdul-Jawad Altisent et al. 72 adding antiplatelet therapy (vs. warfarin alone) use did not reduce the incidence of stroke, major adverse cardiovascular events, or death in patients undergoing TAVI, while increasing the risk of major or life-threatening bleeding. These data were consistent with the WOEST trial results 73 as well as the PIONEER AF-PCI trial results. 74 Similar findings had been reported previously in studies on antithrombotic therapy involving surgical bioprostheses, which suggested that anticoagulation treatment may be implemented for 3-6 months after implantation of a surgical prosthesis while avoiding combinations with aspirin, which is associated with excess bleeding. 13, 18, 75, 76 For patients with a intracoronary stent, if an OAC must be combined with an antiplatelet treatment, it seems preferable to choose clopidogrel rather than aspirin.
Ongoing and further studies will need to address this and other outstanding issues including the role of clopidogrel monotherapy, the need for a loading dose and the potential role of newer P2Y 12 antagonists including prasugrel or ticagrelor in analogy to the combined use of anticoagulation and antiplatelet drugs among patients undergoing percutaneous coronary intervention. 
Role of direct oral anticoagulants post-transcatheter aortic valve implantation
The direct oral factor Xa inhibitors apixaban, rivaroxaban, and edoxaban offer new perspectives in the TAVI era when oral anticoagulation is considered. 77, 78 The rapid onset of action of the direct oral anticoagulants (DOACs) and their favourable safety and efficacy compared with VKAs in the prevention and treatment of thrombo-embolism render them attractive therapeutic options.
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The use of DOACs (instead of antiplatelet treatment) not only in patients with AF but also in those in sinus rhythm after TAVI is currently being investigated in three prospective randomized trials ( 88 For patients on an OAC for AF no adaptations of the regional approved doses for this indication are proposed post-TAVI in ATLANTIS, ENVISAGE TAVI AF, or GALILEO if patients develop new-onset of AF after the TAVI procedure. For patients in sinus rhythm in GALILEO not on an OAC for an established indication, a rivaroxaban 10 mg o.d. dose is selected in combination with low-dose aspirin for 90 days to provide an early, sustained, adequate efficacy in the prevention of thrombotic events and an acceptable safety (bleeding) profile compared with standard of care. 89 The rivaroxaban 2.5 mg b.i.d.
dose, tested in secondary prevention after acute coronary syndrome, was anticipated to lack the desired efficacy given the pro-thrombotic pathophysiology of both AS and the post-TAVI period. In ENVISAGE, one daily dose of edoxaban 60mg (or 30 mg according to dose adjustment criteria) will be used. In ATLANTIS, the same dose of apixaban is considered for all patients, with or without AF.
Role of adjunct devices to reduce neurologic events
A considerable proportion of CVEs occur during the TAVI procedure, and the majority have a thrombotic component. 3, 5, 6, 21, 23 Prevention of peri-procedural CVEs, will rely on the combination of optimal delivery technique of the valve, the development of less traumatic smaller profile devices, all of which reduce catheter manipulation of the aorta, as well as the combination of targeted anticoagulation. In an all-inclusive meta-analysis, embolic protection devices prevented metrics of cerebral embolization, as assessed by MRI, whereas the impact on clinical stroke events remained inconclusive. 90 The use of embolic protection devices remain optimistic in their safety, and may reduce the volume and number of CVEs. 91 Studies are underway to evaluate the role of these devices in reducing neurologic insult during TAVI procedures. [92] [93] [94] The multicentre randomized trial evaluating the role of embolic protection using the Sentinel device during TAVI found that the device was safe although it did not meet the primary efficacy endpoint of reduction in median new lesion volume in protected territories assessed by MRI at 2-7 days. 23 In addition, neurocognitive function was not significantly improved. Importantly, the burden of atherosclerosis and thrombosis at pre-intervention was the stronger predictor of post-TAVI cerebral embolization and neurocognitive score decline.
Role of left atrial appendage closure
In patients with symptomatic severe AS at high bleeding risk with a formal indication for an OAC for AF, the combination of TAVI with a left atrial appendage closure device may provide additional treatment options for patients with AS and concomitant cardiovascular problems.
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Conclusion
Transcatheter aortic valve implantation is an area where scientific data on the balance of efficacy and safety of different peri-procedural and long-term antithrombotic strategies is limited. Clearly, more studies, including the randomized trials described, will be required to Thrombo-embolic protection post TAVI
